The drug was actually phenoxodiol and 'Overture' was the name given to the latest clinical study...phenoxodiol and Novogen was one of the biggest rorts Oz biotech have ever seen....perpetually in phase IIb and phase III trials (nearly a decade all up) and patents on verge of expiring...patent expiry issues very similar to PRR which I recall is 2014...IMO even with potential Orphan drug status patent expiry will be a major issue in PRR securing large scale funding/partnering for CVac
The drug was actually phenoxodiol and 'Overture' was the name...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.010(2.50%) |
Mkt cap ! $566.5M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.5¢ | 38.5¢ | $997.5K | 2.559M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 85852 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 75389 | 4 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |